Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer

Monotherapy with poly ADP-ribose polymerase (PARP) inhibitors results in a limited objective response rate (≤60% in most cases) in patients with homologous recombination repair (HRR)-deficient cancer, which suggests a high rate of resistance in this subset of patients to PARP inhibitors (PARPi). To...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ning, Tian, Yu-Nan, Zhou, Li-Na, Li, Meng-Zhu, Chen, Hua-Dong, Song, Shan-Shan, Huan, Xia-Juan, Bao, Xu-Bin, Zhang, Ao, Miao, Ze-Hong, He, Jin-Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884722/
https://www.ncbi.nlm.nih.gov/pubmed/33589588
http://dx.doi.org/10.1038/s41419-021-03475-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884722/
https://www.ncbi.nlm.nih.gov/pubmed/33589588
http://dx.doi.org/10.1038/s41419-021-03475-4

Ejemplares similares